TORCH Infection in neonate (newborn)

1,462 views 81 slides Sep 17, 2020
Slide 1
Slide 1 of 81
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59
Slide 60
60
Slide 61
61
Slide 62
62
Slide 63
63
Slide 64
64
Slide 65
65
Slide 66
66
Slide 67
67
Slide 68
68
Slide 69
69
Slide 70
70
Slide 71
71
Slide 72
72
Slide 73
73
Slide 74
74
Slide 75
75
Slide 76
76
Slide 77
77
Slide 78
78
Slide 79
79
Slide 80
80
Slide 81
81

About This Presentation

This slide contains clinical features, perinatal and post natal diagnosis of congenital torch infection in fetus and neonates, and management of congenital toxaplasma, rubella, CMV, Herpes simplex, varicella, and other infections.


Slide Content

Dr Md Noor Alam Khan PG-2 Deptt . Of Paeds MAMC Agroha TORCH INFECTIONS

INTRODUCTION 2 Vertically transmitted (mother-to-child) infections of the fetus and newborn can generally be divided into two major categories . Congenital infections : Infections which are transmitted to the fetus in utero . Perinatal infections: which are acquired intrapartum or in the postpartum period.

Congenital infections can have manifestations that are clinically apparent antenatally or postnatally . Whereas Perinatal infections may not become clinically obvious until after the first few days or weeks of life.

4 T = Toxoplasmosis O = Others R = Rubella C = Cytomegalovirus H = Herpes Simplex virus The TORCH acronym has now become Obsolete

TOXOPLASMOSIS

6 Causative Organism : Toxoplasma gondii Transmission : Oocyst excreted in cats feces is the source of infection to humen . Contaminates in soil, water & raw meat. Vertical transmission can occur in utero or during vaginal deliver y The risk of congenital infection increases with gestational age . 6 %- 1 st trimester 22%- 2 nd trimester 72% - 3 rd trimester

The fetal disease severity, however, is inversely proportional to gestational age. 61% - 1 st trimester (mostly die in utero or postnatally / Severe CNS & opthalmological Disease) 30% - 2 nd Trimester (Mostly subclinical/mild) 9% - 3 rd trimester (almost all subclinical/mild ) Highest risk period- 10 to 24 week gestation

Clinical Manifestation Four recognized patterns of presentation for congenital toxoplasmosis. Subclinical Infection: 80-90% Neonatal symptomatic disease Delayed Onset Sequelae or Relapse

Subclinical infection: 80-90% Asymptomatic May have retinal and CNS abnormality Symptomatic Disease: Usually severe Classical Triad of toxoplasmosis : Chorioretinitis Diffuse Nodular Intracranial calcifications Hydrocephalus

Delayed Onset : In preterm Infants within 1 st 3 months like Neonatal Symptomatic Disease Sequelae or relapse: Occurs in 24-85% cases Mainly ophthalmological & neurological symptoms.

14 Common Clinical Manifestation Specific Symptoms; Neurological: Hydrocephalus Seizure Motor deficit Deafness Cerebral Calcification Ophthalmological: Chorioretinitis Cataract Microcornea Necrotising retinitis Cotton Spots on Fundoscopy

Fever Hepatospleenomegaly IUGR Persistant Conjugate Hyperbilirubinemia Anemia Thrombocytopenia Maculopapular Rash Other Symptoms

Diagnosis 1-Maternal Infection Sreening ;- Serum IgG & IgM Confirnatory : IgM ; immunoglobulin A ( IgA ); immunoglobulin, E ( IgE ). Rising titer Avidity Testing Foetal Testing USG Amniotic Fluid PCR

2-In Suspected Neonate Maternal History Clinical examination Lab CBC- thrombocytopenia, Leucocytosis / Cytopenia , Anemia CSF- Elevated protein, Xanthochromia , CT Imaging- Calcifications, hydrocephalus, Cortical Atrophy Pathology- Cyst or trophozoits in tissue, placenta & body fluids Fundoscopy - Chorioretinitis ,

Serological Test- IgG - Appear within 1-2 week Peak at 1-2 months, Persists life long IgM - Not crosses placenta Useful to detect cong infection Low sensitivity IgA - Rises rapidly, disappear by 7 months More sensitive than IgM

MAN A GEM E NT 19 Medications- Pyrimethamine ( 1mg/kg 12 hourly for 2 days, F/B daily for 6month s F/B thrice a week for second 6 months) Sulfadiazine (100mg/kg/day in 2 divided doses for 1 year) Leucovorin (Folinic Acid; 5-10mg thrice a week ) Prednisolone ( 0.5 mg/kg 12hourly) in active CNS disease Surgery- ventricular Shunting

RUBELLA

21 Also known as German Measles Organism: RNA virus, a member of the Togavirus family Transmission : Direct droplet contact from nasopharyngeal secretions virus replicates in the lymph tissue of the upper respiratory tract spreads hematogenously across the place nta

Cause self limited infection in adult Effect on fetus is devasting Fetal infection can occur at anytime, but early gestation infection results in multiple organ anomalies. Gestational age is direct proportional to infection rate and inversely proportional to disease severity.

Infection at 10 week- 100% of infected have cardiac defect and deafness. 13-16 weeks-33% deafness after 20 week – no anomaly Triad of CRS: Cataract SNHL Cardiac Anomaly - PDA>PS

CLINICAL FEATURES General: IUGR, Prematurity, Stillbirth, Abortion CVS: PDA, PAS, CoA Eye: Cataracts, Microphthalmia , Pigmentary (salt -pepper ) Retinopathy Ear: Sensory Neural Deafness GIT: HepatoSpleenomegaly CNS: Meningoencephalitis, Microcephaly, Hypotonia, MR Skin: Blueberry Muffin Rash, Dermatoglyphic abnormalities Blood: Thrombocytopenia Skeletal: Radio-lucencies of long bones 12

25 Blueberry Muffin Rash Blue berry muffin

Rubella Rashes

Salt and pepper fundus

DIAGNOSIS 28 HISTORY OF MATERNAL INFECTION Symptoms - Low-grade fever/Headache/mild coryza and C onjunctivitis occurring 1 to 5 days before the onset of rash. Maculopapular exanthem that begins on the face and the ears and spreads downward over 1 to 2 days. The rash disappears in 5 to 7 days from onset, Posterior cervical lymphadenopathy is common.

29 ANTENATAL DETECTION Specific IgM in Fetal blood obtained by percutaneous umbilical cord blood sampling. Rubella antigen and RNA in a Chorionic villous biopsy specimen. POSTNATAL DETECTION Serology: Detection of Rubella Specific IgM in cord or neonatal blood Persistent IgG titer over time Virus Isolation: pharyngeal secretions/urine sample upto 1 yr

Treatment No specific therapy to halt the progression of complicated CRS. Close follow up if early gestation infection is suspected or timing of infection is unknown. If maternal infection is confirmed: If Gestation <20 weeks Discussfor MTP If Gestation >20 Reasssure parent No risk of abnormalities

31 Supportive care Multi disciplinary approach Hearing loss - hearing aids and referral to an early intervention program Structural cardiac defects – Surgical correction Ocular abnormalities – Referral to Ophthalmology expert CNS abnormalities - special education services, speech, language , occupational, and/or physical therapy. Endocrine abnormalities – Expert Followup for Diabetes/ Hypothyroidism If Baby Born With Rubella Infected Mother

PREVENTION 32 Girls should be vaccinated against rubella before entering the childbearing years Avoid contact to any known or susceptible Rubella infected person. Avoid conception for 3 months following immunization. Hyperimmunoglobulin if infected pregnant female don’t want to terminate pregnency .

CYTOMEGALO VIRUS(CMV)

34 Causative Organism: Cytomegalovirus – DNA virus member of herpes virus family Transmission: Only Human reservoir, lifelong infection Present in saliva , urine , genital secretion, breast milk and blood products. Close contact transmission Route – Transplacental/ Intrapartam/ Postnatal

Primary infection (acute infection)- usually asymptomatic in older infants, children, and adults, may present with mononucleosis like symptoms eg . prolonged fever and a mild hepatitis. Latent infection- Asymptomatic unless host become immunocompromised . Very common, with seroprevalence 50-85% by 40 yrs age.

Primary CMV infection occurs in 1-3% of pregnant women, with a fetal attack rate of 30-40%. 80% of infants with congenital CMV infection will remain asymptomatic . Vertical transmission can occur at any time, infection during early gestation carries higher risk of severe fetal disease. More common among HIV-1 infected infants, so screening for CMV in HIV exposed infants is advised.

Clinical Feature ( A ) Symptomatic congenital disease- Acute fulminant infection- 30% mortality Signs- petechiae / purpura , Hepatosplenomegaly , juandice , prematurity, IUGR(1/3), and “ blueberry muffin spots ” reflecting extra- medullary hematopoiesis . Lab- CBC(anemia, thrombocytopenia), LFT(↑ transaminases and bilirubin )

  Without life-threatening complication- IUGR or disproportionate microcephaly with or without intracranial calcification ( periventricular area ) and chorioretinitis . Other CNS- ventricular dilation, cortical atrophy, develo-pmental abnormalities and neurological dysfunction. SNHL most common sequele (60% symptomatic and 5% asymptomatic infants at birth), so any infant failing newborn hearing screening should be screened for CMV infection.

(B) Asymptomatic congenital infection- • Present in later infancy • Developmental abnormalities, hearing loss, MR, motor spasticity and acquired microcephaly . (C) Perinatally acquired CMV- can be acquired from- • Intrapartum exposure within the maternal genital tract • Postnatal exposure to infected breast milk • Infected blood or blood products • Nosocomially urine or saliva

Almost all full term- remain asymptomatic In preterm infants - acute infection syndrome ( neutropenia , anemia, HSM, lymphadenopathy , hearing loss). (D) CMV pneumonitis - In preterm infants <4 months old

DI A GNOSI S 20 CMV infection diagnosis is made if CMV is identified in urine, saliva, blood or respiratory secretion. Congenital infection- if found in first 2 wks. Perinatal infection- if negative in first 2wks and positive after 4 wks of life. Blood is the earliest specimen to become positive and urine- highest sensitivity for diagnosis of CMV (as CMV is concentrated in urine ).

Neurological outcomes of congenital CMV infection. Examples of computed tomography (A) and magnetic resonance imaging (B and C) of three infants with severe symptomatic congenital CMV infection with CNS involvement are shown. The classical pattern of injury described with congenital CMV infection involving the CNS is characterized by periventricular calcifications (panel A, arrow). Other consequences of fetal brain infection include abnormalities of neuronal migration, leading to polymicrogyria (panel B, arrows) and, in extreme cases, profound structural defects such as porencephalic cysts with associated schizencephaly (panel C, arrow).

- ve blood can’t rule out CMV but – ve urine test in an untreated symptomatic infant for 4 wks or more rule out infection Diagnostic techniques : 1.CMV PCR- in urine or blood. Sensitivity is high for urine, but – ve PCR in blood doesn’t rule out infection. 2. CMV IgG and IgM :- IgG - ve in both maternal and infant sera, excludes congenital CMV infection .

I f IgG + ve in infant sera… Uninfected infant Infected infant IgG declined within 1 month and not Detectable by 4-12 months Continue to produce The I gG through out t he same period CMV specific IgM have limited specificity

MAN A GEMENT 45 For symptomatic congenital CMV Ganciclovir (12mg/kg/day iv infusion 2 div doses for 6 weeks) Valganciclovir -oral and less toxic. Close monitoring & Followup of infected infants

Prevention Personal protective measures(hand washing etc) Avoidance of unnecessary blood transfusion & use of leukocyte depleted blood. If Mononucleusis like illness during pregnency , screen for CMV Infection. Prenatal diagnosis- By viral culture or CMV DNA detection in amniotic fluid, or by CMV IgM antibody measurement in fetal blood of the symptomatic fetus.

HERPES SIMPLEX VIRUS (HSV)

48 Organism: Herpes Simplex Virus(HSV) - DNA virus with two virologically distinct types: 1 and 2 The virus can cause localized disease of the infant's skin, eye, or mouth (SEM) or may be Disseminated disease or CNS disease. Transmission: Contact with genital lesions during delivery: Common Transplacental : Rare.

Clinical Manifestation (A) Localised SEM (skin, eye and mouth infection) 50 % • Vesicles typically appear on the 6th to 9th day of life • Cluster of vesicles on the presenting part of the body (extended direct contact). • Significant morbidity despite in the absence of signs of disseminated disease. • Up to 10% later shows neurologic impairment and infants with keratoconjunctivitis can develop chorioretinitis , cataract and retinopathy.

LESIONS OF NEONATE WITH SEM DISEASE 50 NECK VESICLES SCALP LESIONS

51 EYE VESICLES HYPOPIGMENTED, SCALING, AND CRUSTED EROSIONS OF THE TRUNK AND EXTREMITIES

  (B) CNS infection- • 1/3 of neonates with HSV present with encephalitis in the absence of disseminated disease. • Symptomatic at 8-17 days of life • Hematogenous spread to CNS • lethargy, seizures, temperature instability, hypotonia . • 2/3 have impaired nurodevelopment

(C) Disseminated disease- • Most severe form of neonatal HSV, accounts for 22% of all neonatal HSV. • Mortality >50%, pneumonitis and fulminant hepatitis are associated with greater mortality. • Present with shock, seizures, respiratory distress, respiratory failure, DIC.

DI A GNOS IS 54 For SEM disease - Viral Culture by Isolation – Newer vesicular fluid , Urine & conjunctival smears. For Non SEM disease – PCR of CSF , oral , nasopharyngeal, conjuctival secretion , stool & urine EEG and Imaging studies of brain also aids in the diagnosis of HSV encephalitis Cytology of vesicular fluid – Presence of Tzanck cells

Tzanck cell

MAN A GEMENT 56 Acyclovir Therapy- 60 mg/kg/day 3 div doses SEM disease : Duration for 14 days CNS / Disseminated disease : Duration for at least 21 days, or longer if the CSF PCR remains positive. Infants with ocular involvement : Ophthalmologic evaluation/ Topical ophthalmic antiviral agents in addition to parenteral therapy.

Prevention • Known HSV-2 seronegative woman should avoid sexual intercourse with known HSV-2 seropositive partner in the third trimester. • HSV- 2 primary infection during pregnancy- 10 days course of acyclovir to woman. • Women with HSV-2- test for HIV (as HSV-2 seropositive person have two fold greater risk for acquisition of HIV).

Delivery - offer acyclovir near term until delivery to women with clinical or serological evidence of HSV-2, establishing vaginal route of delivery if no visible lesions Csection in mothers with visible genital lesion

SYPHILIS

Causative Agent- Spirochete, Treponema pallidum Transmission- horizontal- Sexually Vertical – to fetus through Placenta Congenital Syphilis- Transplacental passage of T.Pallidum or contact with infectious lesion during birth. More recent maternal infection, more likely transmission

Clinical Features May result in still birth, hydrops fetalis , prematurity. Mostly Asymptomatic at birth Common signs in <2 years child: Hepatospleenomegaly Condylomata lata Jaundice Snuffles(watery nasal discharge) Anemia Edema Skeletal abnormalities ( Osteochondritis , periostitis )

Common signs in >2 years old child Sensorineural hearing loss Interstitial keratitis Hutchinsons teeth Saddle nose Bony Changes Frontal bossing Short maxilla High palatal arch

Interstitial Keratitis Saddle Nose Hutchinson’s teeth

High Arched Palate Short maxilla

Approach Routine Serological testing for syphilis in all pregnant female Mother with Syphilis( reactive VDRL/RPR and confirmed by reactive TPHA/FTA-ABS Evaluate the infant Assess adequacy of maternal treatment Pathological examination of placenta/ umblical cord Darkfield microscopy Clinical examination of infant Quantitative VDRL/RPR on infant serum(no need of TPHA/FTA-ABS )

SN Scenario Additional Evaluation Treatment 1 Proven/Highly probable disease : Presence of any one Physical abnormalities S/O cong. syphilis OR VDRL/RPR: 4 X high titers than mother’s titer OR Positive darkfield test of body fluids CSFF(VDRL, Cell, protein) CBC, Differential and platelet Count Other test as clinically indicated(long bone and chest X-rays, LFT, neuroimaging , ophthalmologic examination and BERA Penicillin G (1 -1.5 lac unit/kg/day) as 50,000 umits /kg/dose IV for 10 days q 12 h during first 7 days of life q 8 h there after OR Procain Penicillin G 50,000 unit/kg/dose IM OD for 10 days

SN Scenario Additional Evaluation Treatment 2 Possible congenital syphilis: Presence of all 3 Normal physical examination VDRL/RPR ≤ 4 X of maternal titer Mother: not treated/inadequately treated/treated with non Peniciliin regimen/treated <4 week before delivery As above(scenario 1) As above(scenario 1) If complete evaluation not done or uncertain follow up OR Benzathinepenicillin G 50,000 unit/kg/dose IM single dose if Normal complete evaluation and follow up is certain

SN Scenario Additional Evaluation Treatment 3 Congenital syphilis less likely: Presence of all three Normal physical examination VDRL/RPR ≤ 4 X of maternal titre Mother: adequately treated during pregnancy and >4 week before delivery And no reinfection or relapse No evaluation required No treatment required if follow up is certain. Benzathine penicillin G 50,000 unit/kg as a single IM injection if follow up is uncertain

SN Scenario Additional Evaluation Treatment 4 Congenital syphilis unlikely: Presence of all three Normal physical examination VDRL/RPR ≤ 4 X of maternal titre Mother: adequately treated before pregnancy and her VDRL/RPR titre remain low and stable before and during pregnency and at delivery No evaluation required As above (scenario 3)

VARICELLA(Chicken Pox)

Causative agent- Varicella zoster virus , DNA virus of herpervirus family. Primary infection- Chicken pox Reactivation of latent virus(in sensory ganglia)- Zoster Transmission- Horizonta l- Droplet, contact to vesicular lesion Vertical - Mother to fetus through placenta

Risk of congenital varicella syndrome (CVS) is 0.4 % if maternal infection in first 12 weeks of pregnancy 2% for infection in 13-20 weeks. Peripartum Varicella in mother: 25% of newborn develop varicella Severe disease if maternal varicella occurs 5 days before and 2 days after delivery.

Clinical Features (A)Congenital varicella syndrome- C icatrical skin scarring ( cicatrix) L imb hypoplasia O cular defects CNS abnormalities (cortical atrophy ) IUGR Early death. Most commonly occurs with maternal V-ZV infection in 7- 20 wks of gestation.

( B) Postnatal varicella - post natal exposure in newborn period, generally mild disease. Varicella has been detected in breast milk, so it may be prudent to defer breastfeeding at least during the period, mother is likely viremic or infectious.

Approach If maternal rash earlier than 5 days before delivery: Likely hood of infection Isolation Treatment Infant has protective antibodies AND low likely hood of severe disease Do not separate baby from mother, continue breastfeeding, isolate from other infants No VZIG Acyclovir if baby develop rashes

If maternal rash appear with 5 days prior to and 2 days after delivery: Likely hood of infection Isolation Treatment Infant do not have protective antibodies AND likely hood of severe neonatal disease is high Separate mother and baby until maternal lesion dried up If baby develop rash: Baby to stay with mother, isolate both from other infants and mothers VZIG within 72 hours of exposure, Acyclovir

If maternal rash appears after 2 days of delivery: Likely hood of infection Isolation Treatment Infant do not have protective antibodies BUT likely hood of severe neonatal disease is low Separate mother and baby until maternal lesion dried up If baby develop rash: Baby to stay with mother, isolate both from other infants and mothers No VZIG Acyclovir if baby develop rashe

T H A N K Y O U 81